NCT02959138 - Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions

Inflammatory Disease

Interventions

DRUG

Lanraplenib.

20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1

Trial Locations (6)

Clinical Pharmacology of Miami, Inc. (CPMI), Miami

Omega Research Consultants, LLC, Orlando

Orlando Clinical Research Center, Orlando

APEX GmBH, Munich

Auckland Clinical Studies, Grafton

Christchurch Clinical Studies Trust, Christchurch